Top-Rated StocksTop-RatedNASDAQ:IDYA IDEAYA Biosciences (IDYA) Stock Forecast, Price & News $24.87 +0.95 (+3.97%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$23.57▼$24.8950-Day Range$13.33▼$23.9252-Week Range$9.00▼$24.89Volume472,402 shsAverage Volume561,301 shsMarket Capitalization$1.42 billionP/E RatioN/ADividend YieldN/APrice Target$29.40 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability IDEAYA Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside18.2% Upside$29.40 Price TargetShort InterestBearish9.13% of Float Sold ShortDividend StrengthN/ASustainability-0.59Upright™ Environmental ScoreNews Sentiment0.79Based on 4 Articles This WeekInsider TradingSelling Shares$21,436 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.02) to ($2.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.20 out of 5 starsMedical Sector344th out of 983 stocksPharmaceutical Preparations Industry160th out of 486 stocks 3.5 Analyst's Opinion Consensus RatingIDEAYA Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.40, IDEAYA Biosciences has a forecasted upside of 18.2% from its current price of $24.87.Amount of Analyst CoverageIDEAYA Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.13% of the float of IDEAYA Biosciences has been sold short.Short Interest Ratio / Days to CoverIDEAYA Biosciences has a short interest ratio ("days to cover") of 7.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldIDEAYA Biosciences does not currently pay a dividend.Dividend GrowthIDEAYA Biosciences does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIDEAYA Biosciences has received a 76.88% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for IDEAYA Biosciences is -0.59. Previous Next 3.2 News and Social Media Coverage News SentimentIDEAYA Biosciences has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for IDEAYA Biosciences this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for IDYA on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows6 people have added IDEAYA Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IDEAYA Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,436.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of IDEAYA Biosciences is held by insiders.Percentage Held by Institutions94.20% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for IDEAYA Biosciences are expected to decrease in the coming year, from ($2.02) to ($2.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IDEAYA Biosciences is -16.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IDEAYA Biosciences is -16.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIDEAYA Biosciences has a P/B Ratio of 4.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About IDEAYA Biosciences (NASDAQ:IDYA) StockIDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.Read More Receive IDYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address IDYA Stock News HeadlinesMay 30, 2023 | finance.yahoo.comIDEAYA Biosciences to Participate in Upcoming June 2023 Investor Relations EventsMay 27, 2023 | americanbankingnews.comInsider Selling: IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Insider Sells $11,500.00 in StockJune 2, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.May 24, 2023 | msn.comGoldman Sachs Initiates Coverage of Ideaya Biosciences (IDYA) with Buy RecommendationMay 24, 2023 | markets.businessinsider.comAnalyst Expectations for IDEAYA Biosciences's FutureMay 24, 2023 | americanbankingnews.comIDEAYA Biosciences (NASDAQ:IDYA) Hits New 12-Month High at $22.85May 24, 2023 | americanbankingnews.comIDEAYA Biosciences (NASDAQ:IDYA) Now Covered by The Goldman Sachs GroupMay 24, 2023 | americanbankingnews.comBrokerages Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Target Price at $29.11June 2, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.May 22, 2023 | markets.businessinsider.comIDEAYA: FDA Approves To Proceed With Evaluation Of IDE397 In Combination With AMG 193May 22, 2023 | finance.yahoo.comIDEAYA Announces IND Clearance Enabling Phase 1/2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP-Deletion Solid TumorsMay 17, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Cut by Capital One FinancialMay 16, 2023 | markets.businessinsider.comIDEAYA Announces Amended Clinical Trial Collaboration And Supply Agreements With PfizerMay 16, 2023 | finance.yahoo.comIDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal MelanomaMay 16, 2023 | americanbankingnews.comBrokers Offer Predictions for IDEAYA Biosciences, Inc.'s Q2 2023 Earnings (NASDAQ:IDYA)May 13, 2023 | americanbankingnews.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Expected to Earn FY2027 Earnings of $0.29 Per ShareMay 13, 2023 | americanbankingnews.comWedbush Weighs in on IDEAYA Biosciences, Inc.'s FY2027 Earnings (NASDAQ:IDYA)May 12, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Xenon (XENE), IDEAYA Biosciences (IDYA) and Demant (OtherWILLF)May 11, 2023 | americanbankingnews.comIDEAYA Biosciences (NASDAQ:IDYA) Shares Up 4.6% on Better-Than-Expected EarningsMay 9, 2023 | markets.businessinsider.comBerenberg Bank Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)May 9, 2023 | msn.comIDEAYA Biosciences: Q1 Earnings InsightsMay 9, 2023 | msn.comRecap: IDEAYA Biosciences Q1 EarningsMay 9, 2023 | finance.yahoo.comIDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 4, 2023 | finance.yahoo.comWill Entera Bio Ltd. (ENTX) Report Negative Q1 Earnings? What You Should KnowMay 1, 2023 | finance.yahoo.comIDEAYA Biosciences to Participate in Upcoming May 2023 Investor Relations EventApril 29, 2023 | finance.yahoo.comInstitutional investors are IDEAYA Biosciences, Inc.'s (NASDAQ:IDYA) biggest bettors and were rewarded after last week's US$297m market cap gainApril 29, 2023 | americanbankingnews.comIDEAYA Biosciences, Inc. to Post Q1 2023 Earnings of ($0.08) Per Share, Capital One Financial Forecasts (NASDAQ:IDYA)See More Headlines IDYA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IDYA Company Calendar Last Earnings5/09/2023Today6/02/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IDYA CUSIPN/A CIK1676725 Webwww.ideayabio.com Phone(650) 443-6209FaxN/AEmployees81Year FoundedN/APrice Target and Rating Average Stock Price Forecast$29.40 High Stock Price Forecast$40.00 Low Stock Price Forecast$24.00 Forecasted Upside/Downside+21.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,650,000.00 Net Margins-143.90% Pretax Margin-143.90% Return on Equity-20.67% Return on Assets-18.19% Debt Debt-to-Equity RatioN/A Current Ratio11.53 Quick Ratio11.53 Sales & Book Value Annual Sales$50.93 million Price / Sales27.12 Cash FlowN/A Price / Cash FlowN/A Book Value$5.83 per share Price / Book4.14Miscellaneous Outstanding Shares57,290,000Free Float54,368,000Market Cap$1.38 billion OptionableNot Optionable Beta0.84 Key ExecutivesYujiro S. HataPresident, Chief Executive Officer & DirectorAndres Ruiz BrisenoHead-Business Operations & Vice PresidentPaul A. StoneChief Financial Officer & Executive Vice PresidentPaul A. BarsantiChief Technology OfficerMatthew MaurerVP, Head-Medical Affairs & Clinical OncologyKey CompetitorsPliant TherapeuticsNASDAQ:PLRXCatalyst PharmaceuticalsNASDAQ:CPRXTravere TherapeuticsNASDAQ:TVTX89bioNASDAQ:ETNBAurinia PharmaceuticalsNASDAQ:AUPHView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Bought 23,112 shares on 5/22/2023Ownership: 0.757%Jason ThroneSold 500 sharesTotal: $11,500.00 ($23.00/share)JPMorgan Chase & Co.Bought 8,434 shares on 5/18/2023Ownership: 0.064%New York State Common Retirement FundSold 1,825 shares on 5/18/2023Ownership: 0.040%International Biotechnology Trust PLCSold 90,000 shares on 5/18/2023Ownership: 0.033%View All Insider TransactionsView All Institutional Transactions IDYA Stock - Frequently Asked Questions Should I buy or sell IDEAYA Biosciences stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IDYA shares. View IDYA analyst ratings or view top-rated stocks. What is IDEAYA Biosciences' stock price forecast for 2023? 9 brokerages have issued 1-year price targets for IDEAYA Biosciences' shares. Their IDYA share price forecasts range from $24.00 to $40.00. On average, they anticipate the company's stock price to reach $29.40 in the next twelve months. This suggests a possible upside of 21.9% from the stock's current price. View analysts price targets for IDYA or view top-rated stocks among Wall Street analysts. How have IDYA shares performed in 2023? IDEAYA Biosciences' stock was trading at $18.17 on January 1st, 2023. Since then, IDYA shares have increased by 32.7% and is now trading at $24.11. View the best growth stocks for 2023 here. When is IDEAYA Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our IDYA earnings forecast. How were IDEAYA Biosciences' earnings last quarter? IDEAYA Biosciences, Inc. (NASDAQ:IDYA) announced its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.03. The company had revenue of $7.90 million for the quarter, compared to analysts' expectations of $5.38 million. IDEAYA Biosciences had a negative net margin of 143.90% and a negative trailing twelve-month return on equity of 20.67%. The company's quarterly revenue was up 97.5% on a year-over-year basis. What ETFs hold IDEAYA Biosciences' stock? ETFs with the largest weight of IDEAYA Biosciences (NASDAQ:IDYA) stock in their portfolio include Jacob Forward ETF (JFWD), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC), iShares Biotechnology ETF (IBB) and Invesco Nasdaq Biotechnology ETF (IBBQ). What other stocks do shareholders of IDEAYA Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Boeing (BA), Xeris Biopharma (XERS), Entasis Therapeutics (ETTX), Livongo Health (LVGO) and NVIDIA (NVDA). When did IDEAYA Biosciences IPO? (IDYA) raised $70 million in an IPO on Thursday, May 23rd 2019. The company issued 5,000,000 shares at $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO. What is IDEAYA Biosciences' stock symbol? IDEAYA Biosciences trades on the NASDAQ under the ticker symbol "IDYA." Who are IDEAYA Biosciences' major shareholders? IDEAYA Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Logos Global Management LP (7.44%), BlackRock Inc. (7.33%), BVF Inc. IL (4.29%), State Street Corp (3.69%), Price T Rowe Associates Inc. MD (3.03%) and Dimensional Fund Advisors LP (2.14%). Insiders that own company stock include Bvf Partners L P/Il, Jason Throne, Mark Lackner, Michael P Dillon, Michael P Dillon, Paul A Stone, Value Fund L P Biotechnology and Ventures Iv LP 5Am. View institutional ownership trends. How do I buy shares of IDEAYA Biosciences? Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is IDEAYA Biosciences' stock price today? One share of IDYA stock can currently be purchased for approximately $24.11. How much money does IDEAYA Biosciences make? IDEAYA Biosciences (NASDAQ:IDYA) has a market capitalization of $1.38 billion and generates $50.93 million in revenue each year. The company earns $-58,650,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis. How can I contact IDEAYA Biosciences? IDEAYA Biosciences' mailing address is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.ideayabio.com. The company can be reached via phone at (650) 443-6209 or via email at investor@ideayabio.com. This page (NASDAQ:IDYA) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.